Clinical and immunological characteristics for patients in sustained remission and patients who flared
| Clinical features | Sustained remission (n=19) | Flare (n=28) | p Value |
|---|---|---|---|
| Disease duration until treatment (months) | 18 (15–22) | 72 (22–207) | <0.0001 |
| HAQ | 0 (0–0) | 0.5 (0–1.6) | 0.012 |
| RAQoL | 0 (0–2) | 3 (0–11.5) | 0.039 |
| Immunological data | (n=15) | (n=23) | |
| Naives (% of CD4+ T cells) | 10.9 (6.7–14.6) n=12 | 5.4 (4.2–6.0) n=20 | <0.0001 |
| IRC (% of CD4+ T cell) | 28.0 (20.5–33.5) n=13 | 47.0 (36.0–56.0) | <0.0001 |
| Treg CD25highFOXP3+ (% of CD4+ T cells) | 1.5 (1.1–1.8) | 3.2 (2.3–4.0) | 0.001 |
| Treg phenotype | (n=10) | (n=6) | |
| CD62L+ Tregs (% of Tregs) | 70 (61.5–75.5) | 37.5 (30.0–67.8) | <0.0001 |
All values are median (IQR).
Bold type indicates statistically significant differences.
HAQ, Health Assessment Questionnaire; IRC inflammation-related cells; RAQoL, RA Quality of Life Questionnaire; Treg, T regulatory cells.